UK: Is This The End Of SPC Protection For Second Medical Indications In Europe?

Last Updated: 6 February 2019
Article by Chris Goddard

IP practice around Europe is at its most inconsistent when it comes to Supplementary Protection Certificate (SPC) protection for second and further medical indication inventions. A recent Opinion of the Advocate General at the CJEU may point to a pending harmonisation of practice in this area but in a direction that will dismay applicants with inventions in this area.

Supplementary Protection Certificates are "patent term extension" rights which are granted to patent owners with products that require regulatory approval before they can be marketed. Human medicines are the most obvious example, although the system also applies to veterinary medicines and certain agrochemicals. Because patents have a fixed, 20-year, duration, SPC rights are granted as a compensation for the patent term which can effectively be wasted waiting for marketing approval of a product.

In Europe, SPCs are governed by the SPC Regulation (EC 469/2009) which aims to stimulate pharmaceutical research by encouraging pharmaceutical inventions while avoiding giving patent owners limitless periods of exclusivity for old products (so-called "evergreening"). Part of this balance is set out in Art 3 of that Regulation, with Art 3(d) stating:

d) The authorisation referred to in point b) (that covering the product) is the first authorisation to place the product on the market as a medicinal product.

For this purpose, the "Product" is interpreted as being an active agent such as a drug compound. A strict interpretation of Art 3(d) would permit an SPC to be granted only the first time a specific active chemical was marketed, whether that was used for human medicine or in animals. This would reward the development of new active chemicals but not new uses of known materials.

A relatively strict interpretation of the SPC regulation was the norm until 2012 when the "Neurim" referral to the CJEU (C-130/11) changed the landscape significantly. Neurim had developed a product for treating insomnia in humans using the hormone melatonin. However, melatonin had previously been authorised for use in sheep which meant that the UK IPO disallowed Neurim's SPC application on the basis of Art 3(d) above (the human marketing authorisation was not the first). Neurim appealed and ultimately the CJEU judged that they should be allowed an SPC to compensate for the time spent achieving regulatory approval for their product. In the judgement, the CJEU indicated that an earlier marketing authorisation could be ignored if it did not cover anything protected by the patent that was relied on for the new drug. This was a major departure from previous practice and resulted in several patent offices around Europe (including Germany and France) beginning to grant SPCs for new medical uses of old drug compounds (so-called second medical indication inventions). Thus, if a headache medicine was found to protect against heart disease then not only could that discovery be patented but an SPC granted to extend that patent if the need to obtain regulatory approval delayed it reaching the market.

The Neurim decision resulted in many but not all European countries changing their practice on second medical use SPCs with some granting them routinely and others, including the UK, remaining unconvinced. Now, however, a new referral is before the CJEU and looks set to reverse the liberalisation of SPCs seen in Neurim.

This case is another referral to the CJEU (C-443/17) from the English courts, since the UK IPO maintains its practice of interpreting Art 3(d) strictly, and relates to a SPC application by Abraxis for their new formulation of the anti-cancer drug paclitaxel. Paclitaxel is a known drug agent so Abraxis' invention and patent are limited to the new protein-bound nanoparticle formulation that they have developed. They argue that because of this, their patent does not cover any medicine previously authorised and so they should be entitled to an SPC on the basis of the Neurim Judgement.

We only have the opinion of the Advocate General (AG) so far, which is advisory to the court but does not bind it in any way. However, the AG is absolutely savage about the decision in Neurim, setting out why he considers that the court should not have the power to decide as they did in Neurim, why that judgement was based on policy rather than on law and why even that policy may not be a good one. This opinion may not be binding but if the court accepts any of the lines of reasoning set out by the AG then practice on SPCs for second medical indications is likely to be tightening sharply.

The AG sets out four possible outcomes to the Abraxis case:

  1. The court agrees with Abraxis, the SPC is allowed and earlier marketing authorisations are ignored if they only cover materials that are not protected by the new patent;
  2. The court allows for second medical use SPCs in general but not for new formulations as Abraxis have;
  3. The court allows SPCs only where the earlier authorisation was for vetinary medicine and the new authorisation relates to humans (or vice versa); or
  4. The court overturns Neurim and reverts to the position that any prior marketing authorisation will negate all possibility of an SPC on a new invention.

The AG is clearly in favour of option 4) and makes a strong case for that. It's possible that the court might go for option 3), however, since that would allow them to paint Neurim as a special case without having to actually overturn the earlier judgement. Option 1) would only be possible if the court were to completely reject the AG's Opinion and all of the reasoning within it. That's possible but highly unlikely. In any case, if the court can decide clearly on any one of the options above then we will have much more certainty on the interpretation of this article and practice around Europe may begin to unify again. Watch out for the judgement in the next few weeks.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions